OncoMatch/Clinical Trials/NCT07067905

Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma

Is NCT07067905 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies 68Ga-XT771 for clear cell renal cell carcinoma and glioblastoma.

Early Phase 1RecruitingChinese PLA General HospitalNCT07067905Data as of May 2026

Treatment: 68Ga-XT771 — A prospective, open-label, phase 1 study. This clinical trial aims to evaluate the diagnostic value of 68Ga-XT771, a CAIX/CAXII protein-specific probe, in PET/CT imaging for patients with clear cell renal cell carcinoma and glioblastoma. Safety, tolerability, and biodistribution characteristics of 68Ga-XT771 will also be assessed.

Check if I qualify

Eligibility summary

For patients with clear cell renal cell carcinoma or glioblastoma.

This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify